Key statistics
On Friday, Vaccinex Inc (VCNX:NAQ) closed at 4.75, 12.83% above the 52 week low of 4.21 set on Aug 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.51 |
---|---|
High | 4.76 |
Low | 4.50 |
Bid | 4.52 |
Offer | 5.20 |
Previous close | 4.55 |
Average volume | 19.97k |
---|---|
Shares outstanding | 2.60m |
Free float | 1.61m |
P/E (TTM) | -- |
Market cap | 12.35m USD |
EPS (TTM) | -24.59 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
- Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
- Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
- Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
- Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
- Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Vaccinex Reports 2023 Financial Results and Provides Corporate Update
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
- Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
- Vaccinex, Inc. Announces Reverse Stock Split
More ▼